Park Ha Biological Technology Co., Ltd. BYAH
Package Goods/Cosmetics · IPO 2024 · data as of November 13, 2026
Park Ha Biological Technology Co., Ltd. (BYAH) is a consumer discretionary company listed in the US with a market value of about $5M. In fiscal year 2025 it had revenue of $3M and net income of -$24M, a net margin of -965.0%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -60%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 77% below the current price.
About Park Ha Biological Technology Co.
Park Ha Biological Technology Co. is listed in the US and classified in package goods/cosmetics, IPO year 2024. Revenue went from $2M in 2022 to $3M in 2025, growth of about 9.6% a year. It was profitable in 3 of the last 4 years in our data. It spends 9% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $3M | $2M | $2M | $2M |
| Net income | -$24M | $478561 | $852042 | $191298 |
| Free cash flow | -$2973 | $874901 | $103861 | $1M |
| EPS (diluted) | $-7.11 | $0.14 | $0.25 | $0.06 |
| Net margin | -965.0% | 20.1% | 34.6% | 10.0% |
| ROIC | -456.9% | 30.4% | 81.5% | 103.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Park Ha Biological Technology Co. stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 77% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Park Ha Biological Technology Co. pay a dividend?
Not currently.
Is Park Ha Biological Technology Co. a good stock to buy?
We do not give buy or sell advice. Park Ha Biological Technology Co. scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.